Pulse Biosciences Inc
For the period ended Dec 31, 2023. Filed Mar 28, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 28, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of the Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| PULSE BIOSCIENCES, INC. | |||
| Date: March 28, 2024 | By: | /s/ Kevin P. Danahy | |
|---|---|---|---|
| Kevin P. Danahy | |||
| Chief Executive Officer | |||
| (Principal Executive and Principal Financial Officer) | |||
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Kevin Danahy and Timothy Mitsuoka, jointly and severally, as his true and lawful attorney-in-fact and agent, with full power of substitution, each with power to act alone, to sign and execute on behalf of the undersigned any and all amendments to this Annual Report on Form 10-K, and to perform any acts necessary in order to file the same, with all exhibits thereto and other documents in connection therewith with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requested and necessary to be done in connection therewith, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or their or his or her substitutes, shall do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed by the following persons on behalf of the Registrant in the capacities and on the dates indicated.
| Signature | Title | Date |
|---|---|---|
| /s/ Kevin P. Danahy | Chief Executive Officer | March 28, 2024 |
| Kevin P. Danahy | (Principal Executive and Principal Financial Officer) | |
| /s/ Robert W. Duggan | Executive Chairman of the Board of Directors | March 28, 2024 |
| Robert W. Duggan | ||
| /s/ Darrin R. Uecker | Chief Technology Officer and Director | March 28, 2024 |
| Darrin R. Uecker | ||
| /s/ Shelley D. Spray | Director | March 28, 2024 |
| Shelley D. Spray | ||
| /s/ Manmeet S. Soni | Director | March 28, 2024 |
| Manmeet S. Soni | ||
| /s/ Mahkam Zanganeh | Director | March 28, 2024 |
| Mahkam Zanganeh | ||
| /s/ Richard A. van den Broek | Director | March 28, 2024 |
| Richard A. van den Broek | ||
| /s/ Timothy H. Mitsuoka | Corporate Controller | March 28, 2024 |
|---|---|---|
| Timothy H. Mitsuoka | (Principal Accounting Officer) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.